Substitution Of Pegylated Liposomal Doxorubicin For Gemcitabine In Standard Platinum-Based Regimen May Improve Survival In Patients With Recurrent Ovarian Cancer. (4/21, Harrison) reports researchers found in a phase 3 trial that “replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer.” Researchers found that “in a cohort […]
Targeted Oncology (4/13, Columbus) reports, “Frontline niraparib (Zejula) in addition to bevacizumab (Avastin) as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response (PR) to frontline platinum-based chemotherapy with bevacizumab,” phase 2 data show. Findings were issued for the virtual SGO 2020 Annual Meeting. […]
(4/10, Rosa) reported, “The addition of trastuzumab (Herceptin) to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front,” updated phase 2 data demonstrate. In addition, the regimen “led […]
Cancer Therapy Advisor (4/1, Moench) reports that “results of a retrospective analysis of real-world clinical data from patients with ovarian cancer showed a temporal trend for increased rates of BRCA testing in the setting of ovarian cancer, although BRCA testing rates remained suboptimal,” according to findings that “were submitted to the Society of Gynecologic Oncology (SGO) […]
Cancer Therapy Advisor (3/31, Moench) reports that “results of a tumor profiling study of uterine cancer specimens revealed that African-American women were significantly more likely to have uterine cancer characterized as serous carcinoma as well as a higher frequency of TP53-mutated endothelial carcinoma compared with white women.” The “findings were submitted to the Society of Gynecologic […]
Cancer Therapy Advisor (3/30, Moench) reports “results of a large prospective observational study that followed women with early-stage squamous cell carcinoma (SCC) of the vulva characterized by a negative sentinel lymph node biopsy (SLN) at the time of surgery showed these patients to have a low risk of recurrent disease in the groin.” In the study, […]